Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study.
Aged
Antineoplastic Agents, Hormonal
/ therapeutic use
Cancer Survivors
Combined Modality Therapy
Health Status
Humans
Linear Models
Male
Middle Aged
Multivariate Analysis
Prostatectomy
Prostatic Neoplasms
/ pathology
Quality of Life
Radiotherapy
Sexual Dysfunction, Physiological
Social Participation
health-related quality of life
prostate cancer
therapy
well-being
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
06
08
2018
revised:
04
04
2019
accepted:
08
04
2019
pubmed:
3
5
2019
medline:
27
2
2020
entrez:
4
5
2019
Statut:
ppublish
Résumé
Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run. The study sample included 911 survivors with localised PC, 5-15 years post-diagnosis who were identified from the population-based CAESAR + study in Germany. HRQoL was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. The association between type of therapy and HRQoL was assessed with multivariable linear regression and global F-test adjusting for age, time since diagnosis and comorbidities. Overall, survivors treated with radical prostatectomy (RP) or radiotherapy (RT) alone reported the best HRQoL and the lowest symptom burden. Conversely, survivors treated with androgen deprivation therapy (ADT) (& RP/RT) or RP & RT (in combination) reported the worst HRQoL and the highest symptom burden. Significant differences among treatment groups in HRQoL were found for global health status (p = 0.041), social functioning (p = 0.007), urinary symptoms (p = 0.035), bowel symptoms (p = 0.017) and hormonal treatment-related symptoms (p < 0.001) among other symptoms. Long-term localised PC survivors formerly treated with a combination of RP and RT or with ADT report poorer HRQoL and more symptoms than patients treated with either RP or RT alone.
Substances chimiques
Antineoplastic Agents, Hormonal
0
Types de publication
Journal Article
Langues
eng
Pagination
e13076Subventions
Organisme : Deutsche Krebshilfe
ID : 108262
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., … de Haes, J. C. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
Adam, S., Feller, A., Rohrmann, S., & Arndt, V. (2018). Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: A systematic review. Health and Quality of Life Outcomes, 16(1), 22. https://doi.org/10.1186/s12955-017-0836-0
American Cancer Society (2015). Global Cancer Facts & Figures. American Cancer Society, 3(700), 1-57. https://doi.org/10.1002/ijc.27711
American Cancer Society (2000). Cancer Facts & Figures-2000. Atlanta, GA: American Cancer Society.
Arndt, V., Koch-Gallenkamp, L., Jansen, L., Bertram, H., Eberle, A., Holleczek, B., … Brenner, H. (2017). Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncologica, 56(2), 190-197. https://doi.org/10.1080/0284186X.2016.1266089
Cohen, H. J. (2006). Keynote comment: Cancer survivorship and ageing-a double whammy. Lancet Oncology, 7, 882-883. https://doi.org/10.1016/j.critrevonc.2006.06.003.Yabroff
de Rooij, B. H., Ezendam, N. P. M., Mols, F., Vissers, P. A. J., Thong, M. S. Y., Vlooswijk, C. C. P., … Franse, L. V. (2018). Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: The population-based PROFILES registry. Quality of Life Research, 27(12), 3313-3324. https://doi.org/10.1007/s11136-018-1979-0
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., … Neal, D. E. (2016). Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 375(15), 1425-1437. https://doi.org/10.1056/NEJMoa1606221
Dörr, M., Hölzel, D., Schubert-Fritschle, G., Engel, J., & Schlesinger-Raab, A. (2015). Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years. Oncology Research and Treatment, 38(1-2), 8-14. https://doi.org/10.1159/000371717
Drummond, F. J., Kinnear, H., O’Leary, E., Donnelly, N., Gavin, A., & Sharp, L. (2015). Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship, 9(2), 361-372. https://doi.org/10.1007/s11764-014-0419-6
Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H., & Feuer, E. J. (2002). Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute, 94(13), 981-990. https://doi.org/10.1093/jnci/94.13.981
Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual, 3rd ed. (p. 3). Brussels, Belgium: European Organisation for Research and Treatment of Cancer.
Freedland, S. J. (2011). Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer, 117(6), 1123-1135. https://doi.org/10.1002/cncr.25477
Giberti, C., Chiono, L., Gallo, F., Schenone, M., & Gastaldi, E. (2009). Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: A prospective study. World Journal of Urology, 27, 607-612. https://doi.org/10.1007/s00345-009-0418-9
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., … Neal, D. E. (2016). 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine, 375, 1415-1424. https://doi.org/10.1056/NEJMoa1606220
Han, M., Partin, A., Piantadosi, S., Epstein, J., & Walsh, P. (2001). Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. The Journal of Urology, 166(2), 416-419.
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., Van Der Kwast, T., & Mottet, N. (2014). EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent - Update 2013. European Urology, 65(1), 124-137. https://doi.org/10.1016/j.eururo.2013.09.046
Helgstrand, J. T., Berg, K. D., Lippert, S., Brasso, K., & Røder, M. A. (2016). Systematic review: Does endocrine therapy prolong survival in patients with prostate cancer? Scandinavian Journal of Urology, 50(3), 135-143. https://doi.org/10.3109/21681805.2016.1142472
Hoffman, R. M., Gilliland, F. D., Penson, D. F., Stone, S. N., Hunt, W. C., & Potesky, A. L. (2004). Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer, 101(9), 2011-2019. https://doi.org/10.1002/cncr.20608
Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Häggmann, M. … Norlen, B. J. (2002). A Randomized Trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New England Journal of Medicine, 347(11), 781-789.
Hull, G., Rabbani, F., Abbas, F., Wheeler, T., Kattan, M., & Scardino, P. (2002). Cancer control with radical prostatectomy alone in 1,000 consecutive patients. The Journal of Urology, 167(2), 528-534.
Izawa, J. I. (2009). Salvage radiotherapy after radical prostatectomy. Journal of the Canadian Urological Association, 3(3), 245-250. https://doi.org/10.1200/JCO.2009.24.2396
Kupelian, P., Katcher, J., Levin, H., Zippe, C., & Klein, E. (1996). Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical porstatectomy alone for clinically localized prostate cancer. Adult Urology, 48, 249-260.
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., & Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians, 66(4), 271-289. https://doi.org/10.3322/caac.21349
Mols, F., Van De Poll-Franse, L. V., Vingerhoets, A. J. J. M., Hendrikx, A., Aaronson, N. K., & Houterman, S. … Essink-Bot, M. L. (2006). Long-term quality of life among Dutch prostate cancer survivors: Results of a population-based study. American Cancer Society, 107(9), 2186-2196. https://doi.org/10.1002/cncr.22231
National Cancer Institute (2018). Cancer trends progress report. Retrieved August 29, 2018, from https://progressreport.cancer.gov/after/survival#field_most_recent_estimates
National Comprehensive Cancer Network (2014). NCCN Guidelines for Treatment of Prostate Cancer. Retrieved October 7, 2018, from https://www.nccn.org/professionals/physician_gls/default.aspx#site
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., … Smith, M. R. (2015). Adverse effects of androgen deprivation therapy and strategies to mitigate them. European Urology, 67(5), 825-836. https://doi.org/10.1016/j.eururo.2014.07.010
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139-144.
Parker, C., Gillessen, S., Heidenreich, A., & Horwich, A. (2015). Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26, v69-v77. https://doi.org/10.1093/annonc/mdv222
Resnick, M. J., Koyama, T., Fan, K.-H., Albertsen, P. C., Goodman, M., Hamilton, A. S., … Penson, D. F. (2013). Long-term functional outcomes after treatment for localized prostate cancer. New England Journal of Medicine, 368(5), 436-445. https://doi.org/10.1056/NEJMoa1209978
Robert Koch Institut (2017). Zentrum für Krebsregisterdaten. Retrieved August 29, 2018, from https://www.krebsdaten.de/Krebs/DE/Home/homepage_node.html
Royston, P., & White, I. R. (2011). Multiple Imputation by Chained Equations (MICE): Implementation in Stata. Journal of Statistical Software, 45(4), 1-20. https://doi.org/10.18637/jss.v069.i12
Serrell, E. C., Pitts, D., Hayn, M., Beaule, L., Hansen, M. H., & Sammon, J. D. (2017). Review of the comparative effectiveness of radical prostatectomy, radiation therapy, or expectant management of localized prostate cancer in registry data. Urologic Oncology: Seminars and Original Investigations, 36, 183-192. https://doi.org/10.1016/j.urolonc.2017.10.003
Shinohara, N., Maruyama, S., Shimizu, S., Nishioka, K., Abe, T., C-Hatanaka, K. … Shirato, H. (2013). Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. Journal of Radiation Research, 54(6), 1095-1101. https://doi.org/10.1093/jrr/rrt049
Sinding, C., & Wiernikowski, J. (2008). Disruption foreclosed: Older women's cancer narratives. Health, 12(3), 389-411. https://doi.org/10.1177/1363459308090055
Smith, D. P., King, M. T., Egger, S., Berry, M. P., Stricker, P. D., Cozzi, P., … Armstrong, B. K. (2009). Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. British Medical Journal, 339, 12. https://doi.org/10.1136/bmj.b4817
Stattin, P., Holmberg, E., Johansson, J. E., Holmberg, L., Adolfsson, J., & Hugosson, J. (2010). Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study. Journal of the National Cancer Institute, 102(13), 950-958. https://doi.org/10.1093/jnci/djq154
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J. Jr, Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006). Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. Journal of the National Cancer Institute, 98(10), 715-717. https://doi.org/10.1099/mic.0.2008/022293-0.Quantitative
The Union for International Cancer Control's (2019). The Global Cancer Observatory - GLOBOCAN 2018. Retrieved March 18, 2019, from https://www.uicc.org/new-global-cancer-data-globocan-2018
van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., & Aaronson, N. K. (2008). An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418-2424. https://doi.org/10.1016/j.ejca.2008.07.030
Walker, R., Szanton, S. L., & Wenzel, J. (2015). Working toward normalcy post-treatment: A qualitative study of older adult breast and prostate cancer survivors. Oncology Nursing Forum, 42(6), E358-E367. https://doi.org/10.1188/15.ONF.E358-E367
White, I. R., Royston, P., & Wood, A. M. (2011). Multiple imputation using chained equations: Issues and guidance for practice. Statistics in Medicine, 30(4), 377-399. https://doi.org/10.1002/sim.4067
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., … Brawer, M. K. (2017). Follow-up of prostatectomy versus observation for early prostate cancer. New England Journal of Medicine, 377(2), 132-142. https://doi.org/10.1056/NEJMoa1615869